KAGOCEL – proven efficiency!

KAGOCEL is a wide scope antiviral agent used for prevention and treatment of cold and influenza as well as for treatment of herpes in adults.

The agent stimulates synthesis of proteins-interferons pernicious to viruses. Use of the agent helps to relieve symptoms and to speed up recovery.

In the treatment of herpes, KAGOCEL may be used independently or in combination with other anti-herpes drugs which will intensify curative effect.

According to the results of the observational international study «Treatment of ARVI and influenza in FLU-EE routine clinical practice» involving 18, 946 patients from 262 medical centers in Russia, Armenia, Moldova, and Georgia, antiviral drug Kagocel demonstrated high efficiency, regardless of the prescription time and the severity of ARVI and influenza, combined with a high safety profile.
Kagocel significantly accelerates recovery: in the first 24...36 hours after the start of applying Kagocel, the temperature goes down, the intoxication syndrome decreases, and inflammatory processes in the oropharynx change for the better.
Kagocel exerts antiviral action even if treatment starts at a later stage — as late as on the 4th day from the onset of the disease.
High safety profile
Stimulates the production of own interferons possessing high antiviral activity
Provably reduces complications twofold
Suits everyone in the family:
Permitted for use with children from 3 years of age as well as with elderly patients having associated pathologies.
Convenient prevention regimen — to be applied only two times a week.
Kagocel is suitable for routine prevention during the ARVI and influenza season as well as for emergency prophylaxis after contact with an infected person.
Preventive 4-week course of KAGOCEL reduces the likelihood of colds and flu 3 times in the epidemic season.
The effect lasts up to 4 months.


In November 2016, Nearmedic presented the results of a unique post-registration study of the antiviral drug Kagocel in the framework of the international project «Treatment of SARS and influenza in routine clinical practice». The project was carried out jointly with the International Society of Internal Medicine in cooperation with the Eurasian Infectionists Society and the I. M. Sechenov First Moscow State Medical University. The data obtained in the study is unprecedented in scale. The project involved 262 medical centers from Russia, Moldova, Armenia and Georgia and over 18,000 patients aged 18 to 93 years with an established diagnosis of ARVI and influenza. The team of research physicians included primary care specialists, therapists, family doctors and general practitioners.

In the complex therapy of influenza and ARVI, Kagocel demonstrated effectiveness in patients of various ages and of different disease severity degrees, regardless of the time of prescription, including late treatment, against the background of a high level of safety. In the course of therapy with the drug, rapid relief of all the ARVI symptoms (chills, weakness, muscle and joint pains, rhinitis, sore throat, cough, scleritis or conjunctivitis, headache, fever) was noted. The use of Kagocel significantly reduces the number of complications with patients who received systemic antibacterial drugs by 51%.



For four years in a row, Kagocel has been winning the Russian Pharma Award — an award by the community of practitioners of Russia. In 2014, it became the leader in the nomination «Drug of choice for the prevention and treatment of ARVI and influenza». In 2015, 2016, and 2017 it was recognized as the best in the category «The most prescribed drug for the prevention and treatment of SARS and influenza».

Kagocel became the winner of the Green Cross international pharmaceutical award in the category «Drug of the Year», nomination «OTC Drug». According to the voting among specialists of the pharmacy industry, Kagocel was recognized as the best over-the-counter drug of 2015 in Russia for its contribution to the development of the pharmaceutical market and compliance with high quality standards.

In 2017, Kagocel received the Product of the Year award in the category «Antimicrobials for systemic use».

KAGOCEL received the title of Russia’s No.1 non-prescription drug having taken the first place in the 2017 National Pharmaceutical Rating in the nomination «OTC Drug».